Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm Infants

Background/Objective. Hydrocortisone, administered to ventilated preterm neonates to facilitate extubation, has no adverse long-term effects, but short-term pulmonary effects have not been described previously. In the present study, we analyzed effects of hydrocortisone on ventilator settings and Fi...

Full description

Saved in:
Bibliographic Details
Main Authors: Sandra E. A. de Jong, Floris Groenendaal, Frank van Bel, Karin J. Rademaker
Format: Article
Language:English
Published: Wiley 2011-01-01
Series:International Journal of Pediatrics
Online Access:http://dx.doi.org/10.1155/2011/783893
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832559203516940288
author Sandra E. A. de Jong
Floris Groenendaal
Frank van Bel
Karin J. Rademaker
author_facet Sandra E. A. de Jong
Floris Groenendaal
Frank van Bel
Karin J. Rademaker
author_sort Sandra E. A. de Jong
collection DOAJ
description Background/Objective. Hydrocortisone, administered to ventilated preterm neonates to facilitate extubation, has no adverse long-term effects, but short-term pulmonary effects have not been described previously. In the present study, we analyzed effects of hydrocortisone on ventilator settings and FiO2 in ventilator-dependent preterm infants. Patients and Methods. Fifty-five preterm children were included in this retrospective cohort study. Hydrocortisone was administered at a postnatal age of > 7 days to treat chronic lung disease (CLD). Ventilator settings before and after hydrocortisone administration were recorded as well as FiO2 at 36 weeks' gestational age. Presence of cerebral palsy was assessed at a mean corrected age of 24.1 months. Results. Hydrocortisone administered at a median postnatal age of 14 days significantly reduced FiO2 from a median of 0.39 to 0.30, mean airway pressure (MAP) from a median of 10.0 cm H2O to 7.6 cm H2O, and PaCO2 from a median of 53.5 mmHg to 47 mmHg. Extubation was achieved in all patients. CLD at 36 weeks was present in 11 of the 52 patients (21.1%). None developed cerebral palsy. Conclusions. Hydrocortisone was effective in reducing the FiO2, MAP, and PaCO2 and facilitated extubation. Hydrocortisone was not associated with cerebral palsy.
format Article
id doaj-art-45126ed740a64d5fb2e8b8153b23f85c
institution Kabale University
issn 1687-9740
1687-9759
language English
publishDate 2011-01-01
publisher Wiley
record_format Article
series International Journal of Pediatrics
spelling doaj-art-45126ed740a64d5fb2e8b8153b23f85c2025-02-03T01:30:36ZengWileyInternational Journal of Pediatrics1687-97401687-97592011-01-01201110.1155/2011/783893783893Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm InfantsSandra E. A. de Jong0Floris Groenendaal1Frank van Bel2Karin J. Rademaker3Department of Neonatology, University Medical Center Utrecht/Wilhelmina Children's Hospital, P.O. Box 85090, 3508 AB Utrecht, The NetherlandsDepartment of Neonatology, University Medical Center Utrecht/Wilhelmina Children's Hospital, P.O. Box 85090, 3508 AB Utrecht, The NetherlandsDepartment of Neonatology, University Medical Center Utrecht/Wilhelmina Children's Hospital, P.O. Box 85090, 3508 AB Utrecht, The NetherlandsDepartment of Neonatology, University Medical Center Utrecht/Wilhelmina Children's Hospital, P.O. Box 85090, 3508 AB Utrecht, The NetherlandsBackground/Objective. Hydrocortisone, administered to ventilated preterm neonates to facilitate extubation, has no adverse long-term effects, but short-term pulmonary effects have not been described previously. In the present study, we analyzed effects of hydrocortisone on ventilator settings and FiO2 in ventilator-dependent preterm infants. Patients and Methods. Fifty-five preterm children were included in this retrospective cohort study. Hydrocortisone was administered at a postnatal age of > 7 days to treat chronic lung disease (CLD). Ventilator settings before and after hydrocortisone administration were recorded as well as FiO2 at 36 weeks' gestational age. Presence of cerebral palsy was assessed at a mean corrected age of 24.1 months. Results. Hydrocortisone administered at a median postnatal age of 14 days significantly reduced FiO2 from a median of 0.39 to 0.30, mean airway pressure (MAP) from a median of 10.0 cm H2O to 7.6 cm H2O, and PaCO2 from a median of 53.5 mmHg to 47 mmHg. Extubation was achieved in all patients. CLD at 36 weeks was present in 11 of the 52 patients (21.1%). None developed cerebral palsy. Conclusions. Hydrocortisone was effective in reducing the FiO2, MAP, and PaCO2 and facilitated extubation. Hydrocortisone was not associated with cerebral palsy.http://dx.doi.org/10.1155/2011/783893
spellingShingle Sandra E. A. de Jong
Floris Groenendaal
Frank van Bel
Karin J. Rademaker
Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm Infants
International Journal of Pediatrics
title Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm Infants
title_full Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm Infants
title_fullStr Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm Infants
title_full_unstemmed Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm Infants
title_short Pulmonary Effects of Neonatal Hydrocortisone Treatment in Ventilator-Dependent Preterm Infants
title_sort pulmonary effects of neonatal hydrocortisone treatment in ventilator dependent preterm infants
url http://dx.doi.org/10.1155/2011/783893
work_keys_str_mv AT sandraeadejong pulmonaryeffectsofneonatalhydrocortisonetreatmentinventilatordependentpreterminfants
AT florisgroenendaal pulmonaryeffectsofneonatalhydrocortisonetreatmentinventilatordependentpreterminfants
AT frankvanbel pulmonaryeffectsofneonatalhydrocortisonetreatmentinventilatordependentpreterminfants
AT karinjrademaker pulmonaryeffectsofneonatalhydrocortisonetreatmentinventilatordependentpreterminfants